SMV to feature latest clinical work
At its booth at the Society of Nuclear Medicine meeting, nuclear medicine vendor SMV will feature images from recent clinical studies under way to validate new technologies ranging from artifact correction to high-energy coincidence detection imaging.In
At its booth at the Society of Nuclear Medicine meeting, nuclear medicine vendor SMV will feature images from recent clinical studies under way to validate new technologies ranging from artifact correction to high-energy coincidence detection imaging.
In cardiac imaging, the Twinsburg, OH, company will display the latest studies from its Transmission Attenuation Correction (TAC) sites. The sites are demonstrating the value of using TAC on its own and in conjunction with SMV's Stasis motion correction algorithm and Restore depth-dependent resolution recovery technique.
In the coincidence detection realm, SMV will show images from its Volumetric Coincidence Reconstruction (VCR) option, which received 510(k) clearance in March for the Vision FX-80 fixed 180 dual-head camera (SCAN 4/16/97). SMV is waiting for clearance of VCR for its variable-angle cameras, according to Bill Bishop, vice president of business development. SMV will emphasize VCR image quality enhancements with algorithms such as randoms correction.
On the workstation side, the PowerStation SPX and MPX computers will be displayed, with SMV's new Vision 4.1 software. The software includes increased protocol automation, better edge detection, and the addition of Transient Ischemic Dilitation (TID) to SMV's MultiDim 3-D quantification.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
